Treatments for platinum-resistant ovarian cancer are expanding with new FDA-approved immunotherapy combinations and targeted ...

The NHS is to roll out the first new ovarian cancer treatment in more than 20 years. The drug has been shown to extend survival by almost four months for patients whose cancer has stopped responding ...

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer.

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...

Patients in El Paso with certain abdominal cancers now have access to a highly specialized treatment option closer to home ...

Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the ...

Hundreds of women with ovarian cancer are set to benefit after the first new treatment for the hard-to-treat disease in two ...

Peritoneal mesothelioma is a cancer that develops in the membrane that lines the abdomen and its organs, known as the peritoneum. Asbestos exposure is its most common risk factor. Peritoneal ...

Hundreds of women with hard-to-treat ovarian cancer are set to be offered a new treatment following its approval for NHS use.

A new ovarian cancer treatment has been approved for use on the NHS for the first time in 20 years.

Malignant peritoneal mesothelioma is a rare and aggressive cancer that develops in the lining around the abdominal organs. Doctors usually treat it with surgery and chemotherapy. Peritoneal ...